Exiqon A/S has announces that it has signed an agreement to exclusively license a microRNA quantitative real-time PCR technology from Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. The details of the financial terms of the license agreement are not disclosed.
The license agreement with Rosetta provides Exiqon A/S with a validated product portfolio for quantitative analysis of miRNA. The technology has been developed for microRNA biomarker analysis at Merck by Rosetta Inpharmatics and will be implemented in Exiqon’s product line for quantitative real-time PCR detection of miRNA planned for release later this year.
Quantitative PCR is among the most commonly used technologies in biomedical research with over 20.000 installed instruments worldwide and the market for PCR-related products exceeds 1 billion USD annually. The planned launch of a product line for quantitative real-time PCR detection will make Exiqon a total solution provider of research products within miRNA.
The licensed technology and products are enabled by Exiqon’s proprietary LNA technology where including LNA into the invented PCR technology provides highly specific assays with a dynamic range of 7 orders of magnitude.
“This agreement is an important step for Exiqon in order to broaden our product portfolio and to fulfill our ambition of being a total solution provider in the field of miRNA analysis. Being able to market quantitative realtime PCR products for miRNA analysis complements the current product offerings based on microarrays, in situ detection and knockdown products for miRNA research and expands Exiqon’s offerings for microRNA biomarker analysis” says Lars Kongsbak, President & CEO, Exiqon.